anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To realize the adhesive plaster which gradually evaporates effective components, hardly generates the rash of the skin and is used for a human body. CONSTITUTION:The adhesive plaster which is used for the human body and is formed by applying a kneaded material 2 on a substrate 1. This kneaded material contains inorg. porous particulates 3 therein. The components constituting the kneaded material are partly deposited on these inorg. porous particulates 3 or the inorg. porous particulates 3 are made hollow.
PURPOSE:To obtain an agent for treating disturbance of memory and lowering of recognition, containing specific pyrroloquinolines and salt thereof as active ingredients, capable of exhibiting improving action of disturbance of memory and useful in remedy and prevention of cerebral disease. CONSTITUTION:The aimed agent containing a compound substance expressed by the formula (R1 to R4 are H or lower alkyl) and salt thereof. The compound expressed by the formula is obtained by a chemical synthesis as well as produc tion method by microorganism. The above-mentioned treating agent can be normally administered in a form of tablet, granule, capsule, etc., obtained by blending the compound expressed by the formula having effective amount with salts thereof and medicine additive (e.g. carrier, diluting agent or dissolving auxiliary) and preparing from the blend. The resultant preparation is preferably administered orally or parenterally in a dose of 10-600mg/adult.day.
The invention discloses a novel externally applied auxiliary material and a preparation method thereof. The novel externally applied auxiliary material comprises the following raw materials in parts by weight: 18-30 parts of glycerol, 1.5-4 parts of carbomer, 1-4.5 parts of gelatin, 10-36 parts of distilled water, 0.1-2.4 parts of triethanolamine, 0.5-3 parts of polyvinylpyrrolidone and 0.06-0.6 parts of methylparaben. The invention has the characteristics of large loading rate, good appetency of various medicine powder, extractum and the like, unique release effect, strong transdermal effect, good ventilation and closer skin appetency. Compared with the traditional external preparation, the novel externally applied auxiliary material has the advantages of safe manufacturing process, environment protection, no stimulation to skin, no anaphylaxis and comfortable sticking and repeatable uncovering and sticking, stable auxiliary performance and no reaction with main medicines, and is suitable for externally applied preparations manufactured in industrial production, and provides application foundation for externally applied medicine treatment of a plurality of diseases and external use of plant medicines. Meanwhile, the externally applied preparations for medical treatment and cosmeceuticals, which are prepared from the novel externally applied auxiliary material, can be used more conveniently, can maintain water for longer time, has specific release function, and can better achieve the treatment effects. The invention provides an excellent operation platform for externally applied preparation products of medical treatment and cosmeceuticals.
Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Midfoot arthrodesis is regarded as the main surgical approach for treating Müller-Weiss disease (MWD). This study aimed to investigate the incidence of postoperative pain during MWD treatment through midfoot reduction or malreduction during arthrodesis and to explore the factors influencing postoperative pain in patients with MWD.
METHODS: A total of 67 patients with MWD were recruited and divided into two groups according to whether midfoot alignment was reduced: reduction group (n = 38) and malreduction group (n = 29). Demographic characteristics before the operation and at the last follow-up, as well as clinical and radiographic parameters, were compared between the two groups. Clinical parameters included the American Orthopaedic Foot & Ankle Society score and visual analog scale score, whereas radiographic parameters included the calcaneal pitch angle, lateral Meary's angle, talometatarsal-1 angle dorsoplantar (TMT1dp), talocalcaneal angle dorsoplantar (Kite angle), talonavicular coverage angle, and medial navicular pole extrusion. Postoperative complications and incidence of midfoot pain were evaluated at the last follow-up visit.
RESULTS: The reduction group exhibited better clinical and radiological parameters, including the TMT1dp and medial navicular pole extrusion, than the malreduction group at the last follow-up (all P < .05). However, the calcaneal pitch angle, lateral Meary's angle, Kite angle, and talonavicular coverage angle did not significantly differ between the two groups (all P > .05). The overall incidence of midfoot pain was 26.4%. The reduction group showed a lower incidence of medial pain than the malreduction group (15.7% vs. 40.0%, P < .05). Regression analysis revealed that midfoot abduction, represented by the TMT1dp, was a critical factor for midfoot arthrodesis failure and that medial navicular pole extrusion was not correlated with postoperative midfoot pain.
CONCLUSION: Midfoot reduction arthrodesis yields better clinical outcomes than malreduction arthrodesis. The TMT1dp, representing midfoot abduction, is a key factor for midfoot arthrodesis failure. The extruded medial navicular bone may not affect postoperative medial midfoot pain.
LEVEL OF EVIDENCE: Level III, retrospective comparative study.
Precise regulation of gene expression is important for correct neurodevelopment. 9q34.3 deletions affecting the EHMT1 gene result in a syndromic neurodevelopmental disorder named Kleefstra syndrome. In contrast, duplications of the 9q34.3 locus encompassing EHMT1 have been suggested to cause developmental disorders, but only limited information has been available. We have identified 15 individuals from 10 unrelated families, with 9q34.3 duplications <1.5 Mb in size, encompassing EHMT1 entirely. Clinical features included mild developmental delay, mild intellectual disability or learning problems, autism spectrum disorder, and behavior problems. The individuals did not consistently display dysmorphic features, congenital anomalies, or growth abnormalities. DNA methylation analysis revealed a weak DNAm profile for the cases with 9q34.3 duplication encompassing EHMT1, which could segregate the majority of the affected cases from controls. This study shows that individuals with 9q34.3 duplications including EHMT1 gene present with mild non-syndromic neurodevelopmental disorders and DNA methylation changes different from Kleefstra syndrome.
Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 liters per minute (LPM) for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
BACKGROUND: The presence of potato cyst nematodes (PCN) causes a significant risk to potato crops globally, leading to reduced yields and economic losses. While the plant Solanum sisymbriifolium is known for its resistance to PCN and can be used as a trap crop, the molecular mechanisms behind this resistance remain poorly understood. In this study, genes differentially expressed were identified in control and infected plants during the early stages of the S. sisymbriifolium - G. pallida interaction.
RESULTS: Gene expression profiles were characterized for two S. sisymbriifolium cultivars, Melody and Sis6001, uninfected and infected by G. pallida. The comparative transcriptome analysis revealed a total of 4,087 and 2,043 differentially expressed genes (DEGs) in response to nematode infection in the cultivars Melody and Sis6001, respectively. Gene ontology (GO) enrichment analysis provided insights into the response of the plant to nematode infection, indicating an activation of the plant metabolism, oxidative stress leading to defence mechanism activation, and modification of the plant cell wall. Genes associated with the jasmonic and salicylic acid pathways were also found to be differentially expressed, suggesting their involvement in the plant's defence response. In addition, the analysis of NBS-LRR domain-containing transcripts that play an important role in hypersensitive response and programmed cell death led to the identification of ten transcripts that had no annotations from the databases, with emphasis on TRINITY_DN52667_C1_G1, found to be upregulated in both cultivars.
CONCLUSIONS: These findings represent an important step towards understanding the molecular basis underlying plant resistance to nematodes and facilitating the development of more effective control strategies against PCN.
The invention discloses a kind of anti-tumor Chinese medicine and preparation method thereof, belong to tcm field, the present invention is made of several in No. 1 medicine, No. 2 medicines, No. 3 medicines and No. 4 medicines, and No. 1 medicine is made of green peel, kelp, fingered citron, rhizoma cyperi, Radix Curcumae；No. 2 medicines are made of oyster, sea clam, the root of bidentate achyranthes, Ao Jia；No. 3 medicines are made of oldenlandia diffusa, mulberry leaf, radix tetrastigme；No. 4 medicines are made of Radix Notoginseng powder, Asian puccoon, charred RADIX ET RHIZOMA RHEI.The preparation method of the anti-tumor Chinese medicine is to weigh No. 1 medicine, No. 2 medicines, No. 3 medicines and No. 4 medicines respectively, respectively heated by microwave and soup of getting it filled after slow stew.The present invention possesses perfect rational medication system, various medicinal materials is complemented each other, incremental, progressively treats tumour, significant effect, and the preparation method of heretofore described anti-tumor Chinese medicine can be such that the active material in medicinal material is fully absorbed by medicine soup, good drug efficacy.
BACKGROUND: Childhood interstitial lung disease (chILD) encompasses a group of rare heterogeneous respiratory conditions associated with significant morbidity and mortality. Reports suggest that many patients diagnosed with chILD continue to have potentially progressive or fibrosing disease into adulthood. Over the last decade, the spectrum of conditions within chILD has widened substantially, with the discovery of novel entities through advanced genetic testing. However, most evidence is often limited to small case series, with reports disseminated across an array of subspecialty, clinical and molecular journals. In particular, the frequency, management and outcome of paediatric pulmonary fibrosis is not well characterised, unlike in adults, where clear diagnosis and treatment guidelines are available.
METHODS AND RESULTS: This review assesses the current understanding of pulmonary fibrosis in chILD. Based on registry data, we have provisionally estimated the occurrence of fibrosis in various manifestations of chILD, with 47 different potentially fibrotic chILD entities identified. Published evidence for fibrosis in the spectrum of chILD entities is assessed, and current and future issues in management of pulmonary fibrosis in childhood, continuing into adulthood, are considered.
CONCLUSIONS: There is a need for improved knowledge of chILD among pulmonologists to optimise the transition of care from paediatric to adult facilities. Updated evidence-based guidelines are needed that incorporate recommendations for the diagnosis and management of immune-mediated disorders, as well as chILD in older children approaching adulthood.
Coronavirus disease 2019 (COVID-19) and influenza are respiratory illnesses caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses, respectively. Both diseases share symptoms and clinical risk factors1, but the extent to which these conditions have a common genetic etiology is unknown. This is partly because host genetic risk factors are well characterized for COVID-19 but not for influenza, with the largest published genome-wide association studies for these conditions including >2 million individuals2 and about 1,000 individuals3-6, respectively. Shared genetic risk factors could point to targets to prevent or treat both infections. Through a genetic study of 18,334 cases with a positive test for influenza and 276,295 controls, we show that published COVID-19 risk variants are not associated with influenza. Furthermore, we discovered and replicated an association between influenza infection and noncoding variants in B3GALT5 and ST6GAL1, neither of which was associated with COVID-19. In vitro small interfering RNA knockdown of ST6GAL1-an enzyme that adds sialic acid to the cell surface, which is used for viral entry-reduced influenza infectivity by 57%. These results mirror the observation that variants that downregulate ACE2, the SARS-CoV-2 receptor, protect against COVID-19 (ref. 7). Collectively, these findings highlight downregulation of key cell surface receptors used for viral entry as treatment opportunities to prevent COVID-19 and influenza.
Two randomized, vehicle-controlled multicenter trials, Trial 1 (NCT02530281) and Trial 2 (NCT02530294), were conducted in subjects with primary axillary hyperhidrosis and enrolled a total of 697 subjects 9 years of age or older. Inclusion criteria required that prior to the start of treatment, all subjects produce at least 50 mg of sweat in each axilla over a 5-minute period and rate the severity of their sweating daily over a week with a mean score of 4 or higher on the ASDD item #2, a patient reported outcome instrument scored from 0 (no sweating) to 10 (worst possible sweating). The median sweat production over 5 minutes at baseline was 122 mg in the Qbrexza arm and 113 mg in the vehicle arm in Trial 1, and 127 mg in the Qbrexza arm and 117 mg in the vehicle arm in Trial 2. The average weekly mean score on the ASDD item #2 at baseline was approximately 7.2 across both trials.

Subjects were randomized to receive either Qbrexza or vehicle applied once daily to each axilla. The co-primary endpoints were the proportion of subjects having at least a 4-point improvement from baseline in the weekly mean ASDD item #2 score at Week 4 and the mean absolute change from baseline in gravimetrically measured sweat production at Week 4. 

Clinical Response

The results of Trial 1 and Trial 2 are presented in Table 5 below.
PURPOSE: A pharmaceutical composition containing a dibenzylbutyllactone lignan derivative separated from the bark of Torreya nucifera(L.) Sieb. et Zucc. as an active component is provided. The dibenzylbutyllactone lignan derivative protects a liver cell from toxicity induced by carbon tetrachloride and galactosamine and effectively inhibits the proliferation of HSC2 liver. It is, therefore, effectively used in protection of the liver cell and treatment of acute, chronic liver disease. CONSTITUTION: The pharmaceutical composition contains a dibenzylbutyllactone lignan derivative represented by the formula(1) and a pharmaceutically acceptable salt. In formula, R1, R2, R3, R4 and R5 are each independently hydroxyl or methoxy groups. The dibenzylbutyllactone lignan derivative is prepared by extracting the bark of Torreya nucifera in lower alcohol at 20 to 80deg.C for 1 to 3hr, fractioning the extract with dichloromethane and then performing column chromatography.
Students will be required to record their daily step count using a pedometer. Students will be monitored for 3 menstrual cycles. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated.
Interleukin-2 administered subcutaneously, in combination with antiretrovirals, results in an increased CD4+ cell count that might impact upon HIV disease progression. A Phase III trial involving large numbers of HIV-positive patients is the next step in the development process. To develop appropriate clinical experience with this combination, this Phase II trial will allow administration of IL-2 plus antiretroviral therapy to a small number of patients in sites being considered for the Phase III trial.

Patients receive antiretrovirals alone or antiretrovirals plus IL-2 given subcutaneously. Three doses of IL-2 are studied, with 12 patients evaluated at each dose. When at least 9 of the first 12 patients complete the 5-day dosing period without dose-limiting toxicity, the next 12 patients are treated at the next highest dose every 12 hours for 5 days every 8 weeks; when this dose is tolerated, the last 12 patients randomized receive the highest study dose every 12 hours for 5 days every 8 weeks. Patients enrolled at the first two doses of IL-2 who complete three courses of treatment have their dose escalated to a maximum of the highest study dose.
The present invention provides a method of stabilizing insulin chemically at room temperature. Pharmaceutical preparation comprised of dissolving insulin in the choline amino acid ionic liquid Choline- Aspartate (1:1). A primary object of the invention is to provide a pharmaceutical preparation for chemical stabilization of insulin at room temperature , which is comprised of insulin dissolved in choline amino acid ionic liquids with acceptable biological and pharmacological properties. A feature of the present invention is to provide a method for increasing the rate of chemical stability of insulin at room temperature by dissolving it in choline amino acids ionic liquids. An advantage of the present invention is that the method facilitates the chemical stability of insulin at room temperature for at least one year. The ionic liquid Choline Aspartate (1:1) surprisingly was proven to be successful for stabilizing insulin for a period of not less than one year (365 days) at room temperature (10 - 30° C). This ionic liquid is composed of natural, biological, non-toxic materials.
BACKGROUND: The German Arthroplasty Registry (EPRD) recorded nearly 52,000 femoral neck fractures treated with arthroplasty by 2020. This study aimed to identify survival rates and risk factors for hip prosthesis failure.
MATERIAL AND METHODS: The study included all patients with arthroplasty after hip fractures documented in the EPRD. Data were analyzed with focus on failure rate regarding implant, implantation technique, age, BMI, and comorbidities. For more complex analysis of dependencies, the machine learning algorithm (MLA) XGBoost (Extreme Gradient Boosting) was used.
RESULTS: The study included 51,938 patients. The failure rate was 3.7% for HEs and 5.6% for THA. The failure rate increased in male patients (p < 0.0001), those with higher BMI, young patients with a high Elixhauser Comorbidity Score (ECS) and a cementless technique. The timepoint of surgery, i.e. ,working day vs. weekend or holiday had no influence on the outcome. The feature importance (FI) generated by MLA demonstrated factors with the highest impact on failure, i.e., survival time (1029), BMI (722), and age (481).
CONCLUSION: For younger patients with comorbidities, a cemented implantation technique should be considered. Failure rates of arthroplasties did not differ on workdays compared to weekends or holidays. MLA are suitable to analyze registry data for complex correlations of factors.
Patients who have been randomized to receive EN will have a Nasogastric tube (NGT) inserted on day 5 post AHSCT, prior to start of Enteral feeds. This would be a polyurethane tube, 8-10 French, which will be inserted by physician or Nurse Practitioner with position confirmed by radiological examination. This will be if patient intake is \< 80% of usual oral intake at that time. Nutritional support will continue until oral intake is \>50% or until the patient is ready for discharge if intake remains \< 50% of recommendations.
This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
The invention relates to the pharmaceutical industry, namely to the technology of manufacturing pharmaceutical compositions from the tissues of the marine organisms and may be used for obtaining the drug intended for recovery of the malfunctioned surfactant system of the lungs. The technical task of the invention consisted in the elaboration of the method for manufacturing pharmaceutical compositions intended for recovery of the malfunctioned surfactant system based on the novel technology for processing the reproductive organs of the marine organisms allowing for the production of the natural surface-active complex comprising the complex of phospholipids with omega-3 polyunsaturated fatty acids, plasmalogenous phospholipids, the short-chain polypeptides, and amino acids (trade mark Calmophil). The technology consists in crushing the frozen tissues of the reproductive organs of the marine organisms (the eggs and the sperm of the marine fishes and the squids), extracting the raw material with ethanol, separating ethanol extract from the non-extracted material, filtering the extract, evaporating the extract until the complete removal of ethanol, purifying the fraction obtained from hydrocarbons, esters of fatty acids, the products of cholesterol oxidation by the repeated dissolution of the lipid and protein containing fraction in hexane followed by the addition of the aqueous solution of 10 mM CaCl2 in ethanol. Hexane layer is then separated and vitamin E is added (no less than 0.05%). Upon the evaporation of hexane fraction, the lipids obtained are resuspended in physiologic saline solution for 30-60 minutes. Heparin is added at a 1:100:(0.1-0.15) ratio of surface-active substance : physiologic saline solution : heparin. The liposomes are freeze-dried, and the substance of the end-product is obtained.